Recherche et développement dans la résistance bactérienne

Adresse 436 Rue Pierre et Marie Curie 31670 Labège – France

Nombre d'employés 22

Site web

Téléphone 0531471857


Présentation de l'entreprise

“Antabio is a private biopharmaceutical company developing a broad pipeline of novel antibacterial treatments focused on drug-resistant life threatening infections. All Antabio programs address WHO critical priority pathogens and are eligible for streamlined development. Antabio has built a best in class, international team with highly successful track records including former executives from Novexel, Galapagos, Merck, GSK and Astra Zeneca. Antabio’s lead program MBLI (expected to enter the clinic in 2020) addresses a critical global threat that is already highly prevalent in Asia-Pacific. The company is targeting strategic partnerships in Asia-Pacific to maximize its peak sales potential. Antabio has raised over €18m in non-dilutive financing to date from Wellcome Trust (2 SDD awards, 2013 and 2015) and CARB-X (2017).  The company also completed a €12,5m series A round in 2017 with second closing in 2018.” From